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Objectives: We investigated the association between aldosterone (ALDO)
and renin (REN) plasma levels with early changes of cardiovascular structure
and function involved in the progression to heart failure (HF) in subjects with
abdominal obesity (AO).
Background: Incidence of HF doubles in AO. This condition is associated
with an activation of the renin angiotensin aldosterone system, which may be
involved in the progression to HF.
Methods: AO subjects matched for age and sex to healthy volunteers (HV)
underwent ALDO and REN measurements and cardiac and arterial pheno-
typing to explore early remodeling (trans-thoracic echocardiography, cardiac
magnetic resonance imagery, intima-media thickness measurement, pulse
wave velocity, and fibrosis biomarkers).
Results: 116 AO subjects (BMI: 31.7±3.4 kg/m²) aged 55±6 years and 53
HV were recruited. AO subjects had higher ALDO (59 (33-106) vs 34 (18-65)
pg/ml, p<0.0001), left ventricular mass (LVM) (97±25 vs. 84±21 g, p=0.003),
and cardiac remodeling index (CRI=LVM/LV End Diastolic Volume)
(0.69±0.16 vs. 0.60±0.10 g/ml, p=0.004). AO subjects also had higher serum
levels of the extracellular matrix turnover (PINP: 36±16 vs. 22±14 g/ml,
p<0.0001; PIIINP: 2.6±1.3 vs. 3.4±6.7g/ml, p=0.082; ICTP: 3.9±1.0 vs.
4.6±0.9 g/ml, p<0.0001). In the multivariate analysis REN was significantly
correlated with LVM (p=0.036) and CRI (p=0.009). PIIINP (p=0.043) was
independently correlated with diastolic dysfunction.
Conclusions:. In AO, there is an early rise in ALDO and early changes of
extracellular matrix remodeling and cardiac geometry that were correlated to
REN. Renin might be a target for the prevention of early cardiac remodeling
and progression to HF in AO patients.
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Long-term follow-up after myocardial contrast echocardiography-gui-
ded alcohol septal ablation for hypertrophic obstructive cardiomyopa-
thy
Amir Fassa [Orateur], Thierry Lefèvre, Marie-Claude Morice, Jean-Fran-
çois Piéchaud, Marie-Christine Malergue, Yves Louvard, Philippe Garot,
Bertrand Cormier
Institut Hospitalier Jacques Cartier, Institut Cardiovasculaire Paris Sud,
Massy, France
Aim: Report the immediate and long-term results of alcohol septal ablation
(ASA) guided by myocardial contrast echocardiography (MCE) for treatment
of symptomatic hypertrophic obstructive cardiomyopathy from a high-volume
centre.
Methods and results: From 2000 to 2011, 159 patients (88 males) under-
went ASA. Mean age was 56.4±15.9 years (range 8-87). Medical treatment
included beta-blockers (75%), calcium-channel antagonists (49%) and disopy-
ramide (2%). 22% had prior pacemaker (PM) implantation, 2% prior implant-
able cardioverter-defibrillator (ICD) and 4% prior cardiac surgery. At
baseline, mean New York Heart Association (NYHA) functional class was
2.8±0.6. Mean left ventricular outflow tract (LVOT) peak gradient and septal
thickness were 92±45 mmHg and 23.0±3.8 mm, respectively. During ASA,
2.0±0.8 ml of absolute alcohol was injected in 1.2±0.4 septal perforators.
Final procedural LVOT peak gradient was 20±22mmHg. Procedural success
(immediate LVOT peak gradient reduction >50%) was achieved in 94%.
Complications included coronary dissection requiring stent implantation (1
procedure). There were 2 in-hospital deaths (1 refractory ventricular
arrhythmia, 1 complete atrioventricular block). In-hospital permanent PM
implantation was required following 8.7% of procedures. One patient required
an ICD for non-sustained ventricular tachycardia. Mean peak CK was
932±491 IU/L. At a mean follow-up of 2.3±1.8 years after the procedure
(range 0-8.4), there were 7 additional deaths (overall annual mortality of 2%).
Repeat ASA was required in 11 patients (7%) and a new ICD was needed in
1 patient (5%). Mean NYHA class was improved to 1.2±0.5.
Conclusion: MCE-guided ASA is associated with a high rate of immediate
success and a low rate of procedural complications. In addition, long-term
follow-up shows sustained clinical benefit with a low rate of adverse events
(annual mortality lower than the expected rate of 3-4% in this high-risk pop-
ulation).
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Cardiovascular disease in acromegaly is multiple pathogenic mechanisms
(high blood pressure (hypertension), valve disease, coronary atherosclerosis,
diabetes ...) but also by a proper action of human growth hormone (GH) on
the myocardium. The acromegalic cardiomyopathy is the most common, it is
the leading cause of mortality in acromegaly.
Purpose, Materials and Methods: We propose in this retrospective study
to report on the cardio-vascular clinical profile, echo-cardiographic (size cav-
ities, cardiac mass, valvular thickening, valvular leakage, systolic and diastolic
function) and changing (before and after treatment and medical or surgical) of
20 acromegalic patients followed concurrently with doctors endocrinologists.
Results: The population is predominantly male (70%) whose mean age
was 47.21±15.81 (range: 27-67 years) 30% of patients under 40 years 40% of
patients were hypertensive and 50% have diabetes. The diagnosis of acrome-
galy is sometimes late compared to early clinical signs: 9.9±8.6 years (range
1-30 years).
Conclusion: Morbidity and mortality associated with acromegaly is con-
sidered equivalent to the general population according to recent studies
Results 
Before treatment After treatment
CLINICAL FEATURES
Dyspnea (NYHA stage) II (4 pts) II (2 pts)
Congestive Heart 0 0
LVH 13 (65%) 9 (45%)
Arrhythmia / conduction 0 0
Repolarization disorder 1 1
MI failure 1 1
Hypertension 8 (40%) 5 (25%)
Diabetes 10 (50%) 8 (40%)
SONOGRAPHIC FEATURES
EF (%) 70,5±8,3 72,1 ±10,3
Septal thickness (mm) 12,04±2,8 11,01 ±4,9
Post Wall Thickness (mm) 12,04±2,8 10,11 ±4,2
Myoc Masse (g/m2) 167±42 138 ±63
Thickening M/Ao =9 3/6 3/6
E/E’ 13,09±4,9 8,2±3,7
E deceleration time 271±46 199±38
PAPS 34,9±4,9 34,9±4,9
Mitral regurgitation (grade 1) I (1/3) I
Ao regurgitation (grade 2) I (1/6) II (1/6) I et II
Cardiac output 7,3±1,9 5,5±4,2
